NEW YORK (GenomeWeb News) – Vela Diagnostics today announced a deal with Thomas Jefferson University and Hospitals to jointly develop molecular diagnostics aimed at cancer and infectious diseases.

The Singapore-based company said the two partners are currently deciding on several projects, including developing next-generation- and PCR-based assays. Using new technologies, Thomas Jefferson will help VelaDx develop and validate the assays. VelaDx will seek regulatory approval for the assays on a global basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.